see treatment of manifestations	13
hematopoietic stem cell transplantation (hsct)	5
enzyme replacement therapy (ert)	5
val804met+p	4
see agents/circumstances to avoid	3
see therapies under investigation	3
other	3
none	3
8 yrs	3
dietary management	3
antioxidants	3
prevention of secondary manifestations	2
appropriate measures include the following:	2
breast cancer	2
bone marrow transplantation (bmt)	2
prevention of acute attacks	2
liver transplantation	2
dietary guidelines for hereditary fructose intolerance (hfi)	2
adapted from www	2
edu/aldolase/hfi/treatment/sugar_table	2
htm	2
risk for aggressive mtc based on genotype and recommended interventions	2
20 yrs	2
ata = american thyroid association	2
ser649leu and p	2
hpt = hyperparathyroidism	2
pathogenic variants in cis configuration on one allele	2
criteria: normal annual basal and or stimulated serum calcitonin	2
normal annual neck ultrasound examination	2
family history of less aggressive mtc	2
organ transplantation	2
pathophysiology	2
low-fat diet	2
no formal guidelines for amount of dietary fat exist	2
multiple small meals	2
no evidence-based guidelines exist	2
good hydration	2
gene therapy	2
antibiotic prophylaxis	2
most affected individuals are clinically normal at birth	1
hb bart syndrome	1
no specific treatment is available for the sensorimotor neuropathy	1
lifestyle and dietary modification to avoid known triggers	1
bmt/sct from a “non-ideal” donor	1
ert is not curative	1
more than 300 affected individuals have received peg-ada	1
in individuals who lack an hla-identical donor)	1
chan et al 2005	1
kaufman et al 2005	1
husain et al 2007	1
author, unpublished data]	1
a third affected individual died of hepatoblastoma after 2	1
5 years of ert	1
these are of no clinical significance	1
seek timely treatment of systemic illness or infection	1
avoid excessive alcohol consumption and smoking	1
regular weight-bearing exercises are encouraged to maintain bone health	1
restriction of dietary protein through use of specialized formulas	1
administration of oral nitrogen scavenging drugs	1
9-13	1
0 g/m2/day in larger patients	1
diet	1
arginine base supplementation	1
8-15	1
oral nitrogen scavenging therapy	1
orthotopic liver transplantation (olt)	1
management relies on personalized recommendations based on clinical assessment	1
implantable cardioverter-defibrillators (icds)	1
syncope was found to predict appropriate icd discharge	1
class ii indications (i	1
uveal melanoma	1
malignant mesothelioma	1
cutaneous melanoma	1
complete sunblock should be used	1
avoidance of triggers/stressors including trauma and surgery	1
no preventive or curative treatment is available for bhds	1
biotin therapy is lifelong	1
a protein-restricted diet is not necessary	1
branchial arch anomalies can be surgically corrected	1
consider prophylactic bilateral mastectomy	1
chemoprevention	1
the sample size, however, was extremely small	1
ovarian cancer/fallopian tube cancer	1
salpingectomy	1
tubal ligation	1
there are no preventive measures for stroke or vascular dementia	1
salt-wasting crisis	1
flu prevention (i	1
a later age of onset of symptoms	1
strict avoidance of sunlight and protection from light are indicated	1
antibacterial prophylaxis	1
antifungal prophylaxis	1
immunomodulatory therapy	1
9 months	1
13 to 0	1
4 per patient year	1
the data for this are anecdotal and unimpressive	1
for bsa >0	1
for bsa ≤0	1
5/m2 the dose is 1	1
5 μg/kg subcutaneously 3x/week	1
allogeneic hsct is the only known cure for cgd	1
, aspergillosis)	1
high-carbohydrate meals and alcohol should be avoided	1
arginine administration may be effective in preventing hyperammonemic crises	1
aro	1
a schulz and u kornak, unpublished results]	1
schulz and moshous, personal communication]	1
these individuals should receive prophylactic anticholinesterase therapy	1
no treatment reverses or slows the natural progression of cmt	1
infusions of glucose during intercurrent infections to prevent catabolism	1
note: oral glucose cannot achieve this effect	1
frequent meals and avoidance of extended fasting	1
avoidance of prolonged exercise and other known triggers	1
3 to 1	1
95 g/m2/day)	1
procysbi® is taken every 12 hours	1
cysteamine increases gastrin synthesis and gastric acid production	1
55% solution with benzalkonium chloride 0	1
recommended drugs are nadolol (1-2	1
granulocyte colony-stimulating factor (g-csf)	1
dale, unpublished observations]	1
, 5-10 µg/kg/day)	1
for individuals with ts-nsan:	1
prevent febrile episodes	1
physical therapy may prevent early joint contractures	1
as such, empiric recommendations include the following:	1
supplement with levocarnitine if deficient	1
avoid liver-toxic medications	1
acetazolamide could stabilize channels that fail to properly inactivate	1
use of soft and properly fitted clothing and footwear	1
however, there is no limitation	1
note: when indicated, splenectomy is curative	1
2 mg/kg every 2 weeks)	1
06) [banikazemi et al 2007]	1
the largest comparative study is the canadian fabry disease initiative	1
3 g/kg every other week	1
and compliance should be closely monitored	1
prophylactic anticoagulation	1
pregnancy	1
prophylactic anticoagulation during pregnancy:	1
pharmacologic and surgical interventions have focused on palliation of symptoms	1
weighted gloves can sometimes be used to assist with dysmetria	1
ablative pallidotomy or thalamotomy	1
colchicine	1
homozygotes/compound heterozygotes	1
individuals who are homozygous for the pathogenic variant p	1
met694val or compound heterozygous for p	1
children may need 0	1
5-1 mg/day according to age and weight	1
affected individuals should receive colchicine for life	1
individuals who do not have the p	1
glu148gln	1
heterozygotes	1
treatment of affected individuals who are unresponsive to colchicine	1
some individuals appear to be unresponsive to colchicine treatment	1
weekly intravenous colchicine (1	1
this is not a long-term solution	1
the possibility of interferon alpha side effects (e	1
, chills and fatigue) should also be considered	1
sulphasalazine	1
she was homozygous for the pathogenic variant p	1
dietary intervention	1
, isomil® or prosobee®)	1
furthermore, such tests may not be available	1
, combined ert and bmt)	1
it is likely that end-stage histologic changes (e	1
ert is well tolerated	1
adverse effects (e	1
, brain, bones, and lungs)	1
substrate reduction therapy (srt)	1
6 to -0	1
crim status	1
age restrictions on lumizyme were removed in 2014	1
many individuals are now treated with the higher dose	1
complications of ert	1
infusion-associated reactions	1
prognosis	1
iopd	1
lopd	1
the major morbidities are motor disability and respiratory insufficiency	1
see treatment of manifestations and agents/circumstances to avoid	1
liver phk deficiency	1
hypoglycemia	1
6 to 2	1
some individuals may require cornstarch only before bedtime	1
requirements for cornstarch tend to lessen with age	1
muscle phk deficiency	1
however, regular moderate aerobic exercise may be beneficial	1
involves the following:	1
selection of appropriate contraception for females	1
a copper-eluting iud is theoretically the safest in porphyria	1
however, little information exists	1
suppression of menses using a gnrh agonist	1
, propofol, ketamine, short-acting benzodiazepines)	1
does not	1
involve the following:	1
use of glucose	1
extreme diets (e	1
no known treatment stops or slows the progression of hdl2	1
5 to three years	1
the following measures are recommended:	1
avoidance of drugs and agents that induce the hepatic p450	1
vaccination against hepatitis a and b	1
table 3	1
food category	1
foods permitted	1
foods prohibited	1
dairy	1
any milk, cheese, eggs	1
meat	1
beef, veal, lamb, pork	1
ham, bacon, hot dogs, processed meats	1
any other meat where sugar is used in processing	1
fish	1
all fish	1
poultry	1
chicken, turkey	1
cereal	1
sweetened/sugar-coated cereals	1
fruit	1
vegetables	1
all other vegetables, including sweet potatoes	1
bread	1
soda crackers & saltines	1
any breads or crackers prepared w/fructose/sucrose/sugar/sorbitol	1
fat sources	1
desserts and sweeteners	1
dietetic jello, dietetic ice cream, dietetic puddings	1
natural yogurt	1
sugar, sucrose, sorbitol, fructose	1
miscellaneous	1
some sugar substitutes	1
some dietetic beverages	1
pasta	1
rice	1
cinnamon, garlic, poppy seeds	1
peanut butter if prepared w/added sugars	1
chewing gum w/sorbitol	1
the following are recommendations:	1
biopsy-proven diffuse-type gastric carcinoma	1
heterozygotes for a germline cdh1 pathogenic variant	1
however, the morbidity from prophylactic gastrectomy is high	1
the age-specific risks of gastric cancer	1
citrulline supplementation at 0	1
17 g/kg/day or 3	1
lysine supplementation is indicated when plasma lysine concentrations are low	1
liver transplantation is not indicated for persons with hhh syndrome	1
betaine therapy is usually added to the therapeutic regimen	1
details about each aspect of treatment follow	1
vitamin b6 (pyridoxine) therapy	1
dietary treatment	1
this diet should be continued indefinitely	1
folate and vitamin b12 supplementation	1
betaine treatment	1
side effects of betaine are few	1
acetazolamide treatment:	1
is beneficial in approximately 50% of individuals with hokpp	1
has no effect in 30% of affected individuals	1
alternatives to acetazolamide	1
pinacidil [ligtenberg et al 1996]	1
and bumetanide [wu et al 2013]	1
5 mg/kg	1
more recently, in a 3	1
long-term use of ert was safe	1
and	1
, infliximab)	1
itching	1
rash	1
flushing	1
and headache	1
treatment of hyperuricemia with allopurinol can prevent development of gout	1
diet/environment	1
potassium-rich medications and foods (e	1
, fruits, fruit juices)	1
fasting	1
strenuous work	1
exposure to cold	1
diuretics	1
preventive measures include the following:	1
statin-based therapy with addition of other medications as needed	1
reduced intake of saturated fat	1
increased intake of soluble fiber to 10-20 g/day	1
increased physical activity	1
not smoking	1
see treatment of manifestations, clonazepam	1
bmt is currently the only cure for ipex syndrome	1
treatment by phlebotomy in presymptomatic stages can prevent organ damage	1
treated individuals show improved and preserved cognitive function	1
thiamine transporter deficiency (mutation of slc19a3)	1
biotinidase deficiency (btd)	1
coenzyme q10 biosynthesis defect (pdss2)	1
, prolonged lethargy, depression)	1
up to ten hours during the second year of life	1
up to 12 hours after age two years	1
to avoid excessive fasting:	1
infants require frequent feedings	1
a relatively low-fat diet (e	1
kidney transplantation cures adtkd-umod	1
the transplanted kidney does not develop the disease	1
no specific treatment for melas exists	1
prophylactic thyroidectomy is safe for all age groups	1
table 4	1
ata 1 risk level	1
pathogenic variants 2, 3	1
age of prophylactic surgery	1
age to begin screening	1
for pheo	1
for hpt 4	1
level d(highest risk)	1
ala883phep	1
met918thrp	1
glu805lys 5p	1
tyr806cys 5p	1
ser904cys 5	1
as soon as possible in 1st year of life	1
level c	1
cys634arg/gly/phe/ser/trp/tyr	1
<5 yrs	1
level b	1
cys609phe/arg/gly/ser/tyrp	1
cys611arg/gly/phe/ser/trp/tyrp	1
cys618arg/gly/phe/ser/tyrp	1
cys620arg/gly/phe/ser/trp/tyrp	1
cys630arg/phe/ser/tyrp	1
asp631tyrp	1
633/9 bp dupp	1
634/12 bp dupp	1
val778ile 5	1
consider <5 yrs	1
may delay if criteria met 5	1
level a	1
arg321glyp	1
531/9 bp dupp	1
532 dupp	1
cys515serp	1
gly533cysp	1
arg600glnp	1
lys603glup	1
tyr606cysp	1
635/insert elcr	1
thr636prop	1
lys666glup	1
glu768aspp	1
asn777serp	1
leu790phep	1
val804leu/metp	1
gly819lysp	1
arg833cysp	1
arg844glnp	1
arg866trpp	1
ser891alap	1
arg912pro	1
may delay beyond age 5 yrs if criteria met 6	1
six months for children with men 2b	1
menkes disease	1
occipital horn syndrome	1
medicalert	1
org)	1
they reflect evolving pretreatment conditioning and improved donor matching	1
hsct failures continue	1
nevertheless, some improvement has been seen	1
nutrition	1
after stabilization, nutritional management is critical	1
a propiogenic amino acid-deficient formula (e	1
isolated valine or isoleucine supplementation should be avoided	1
hydroxocobalamin injections	1
antibiotics	1
rotating antibiotic regimens may be considered in some persons	1
kidney transplantation	1
a second patient developed progressive neurologic symptoms	1
and two others developed metabolic decompensations post transplant	1
adults have not undergone hsct	1
all published reports indicate that ert is well tolerated	1
hepatic volume normalized in 92%	1
respiratory function either improved slightly or remained constant	1
timed walk measurements remained largely constant	1
growth resumed in approximately 70%	1
the most common reactions were of an immune nature	1
other studies have shown:	1
5-4	1
see treatment of manifestations for information regarding ert	1
normal weight gain, linear growth, and head growth	1
home formula supplies include bcaa-free powder	1
normal age- and weight-adjusted energy intake	1
appropriate leucine tolerance	1
goals of laboratory monitoring:	1
plasma isoleucine concentration approximately equal to plasma leucine concentration	1
plasma valine concentration at least twofold plasma leucine concentration	1
thiamine treatment	1
9-20	1
mt-rnr1-related aminoglycoside-induced ototoxicity	1
thrombocytopenia cannot be prevented	1
oral contraceptives are often effective in preventing or controlling menorrhagia	1
exercise temporarily alleviates myotonia (the warm-up effect)	1
the effect has not been systematically studied	1
treatment and monitoring may then start immediately	1
variable results have been reported with hsct	1
enzyme replacement therapy	1
skin that burns with sun exposure needs protection	1
an early (pediatric) dermatologic consultation is warranted	1
all primary manifestations are present at birth	1
however, small meals may minimize pancreatic exocrine stimulation	1
circumstances to avoid	1
dehydration worsens episodes of acute pancreatitis	1
no curative therapy is presently available for pbd, zss	1
consistent, regular care of the conditions is necessary	1
minimize intercurrent infections as environmental stressors	1
5 mg for infants and 2 mg for adults	1
studies have indicated that higher doses may enhance intellectual development	1
such therapy is required for life	1
always maintain good hydration	1
avoid activities that potentially increase blood viscosity (e	1
, mountain climbing, scuba diving, smoking)	1
severe atp8b1 deficiency	1
mild atp8b1 deficiency	1
vaccination against hepatitis a and b is appropriate	1
acute attack	1
weekly or biweekly hemin infusions may prevent frequent noncyclical attacks	1
however, published experience is lacking	1
photocutaneous	1
pre-prandial plasma essential amino acids	1
plasma albumin	1
prealbumin	1
hemoglobin	1
plasma ammonia	1
plasma vitamin d	1
essential fatty acid profile	1
additional calories can be provided using protein-free formulas	1
medications	1
levocarnitine	1
the optimal dose of levocarnitine has not been established	1
levocarnitine can be given enterally and intravenously	1
antimicrobial therapy	1
biotin supplementation	1
management during episodes of metabolic decompensation includes:	1
avoidance of fasting (e	1
, using intravenous dextrose)	1
increasing calorie intake to prevent catabolism (e	1
, intravenous fat emulsion)	1
olt in patients with pa is not curative	1
sedation and perioperative management	1
emergency situations	1
prevention of primary manifestations in hereditary pancreatitis is limited	1
no curative therapy currently exists for refsum disease	1
see treatment of manifestations, pharmacologic treatment	1
beta blockers	1
icd	1
ongoing education is essential to help minimize morbidity and mortality	1
maintaining hydration and avoiding extremes of climate	1
monitoring for signs and symptoms requiring acute medical intervention	1
early detection of chronic complications	1
updates on new therapies	1
chronic red blood cell transfusion therapy	1
prevention of stroke recurrence	1
treatment of chronic pain refractory to other therapies	1
pulmonary hypertension	1
chronic renal failure	1
recurrent episodes of acs	1
severe end-organ damage	1
metabolism into nitric oxide, a potent vasodilator	1
overall improvement in blood flow	1
reduction of vascular inflammation	1
hydroxyurea can have potentially significant toxicity, including myelosuppression	1
gov/ct2/show/nct01179217)	1
orthotopic liver transplantation (oltx)	1
age younger than 60 years	1
disease duration less than five years	1
no significant cardiac or renal dysfunction	1
fapwtr	1
org/ram_fap	1
severe polyneuropathy (norris score <55/81)	1
permanent urinary incontinence	1
marked postural hypotension	1
a fixed pulse rate	1
[behrend et al 2012]	1
however, the efficacy remains controversial	1
severe exercise (e	1
infection	1
intravenous immune globulin	1
routine childhood immunizations	1
live vaccines should be avoided	1
bleeding	1
splenectomy	1
platelet transfusions	1
platelet transfusions should be administered judiciously (e	1
, for significant bleeding and surgical procedures)	1
hla-matched bone marrow transplantation from a relative is preferred	1
cord blood from normal infants is now being banked	1
bmt after age 3	1
administration of immunoglobulin	1
see also therapies under investigation	1
bacterial infections	1
both routes provide good therapeutic concentrations of serum igg	1
a variety of brands of gammaglobulin are available	1
such reactions may disappear over time	1
the following methods are used to prevent infection:	1
intravenous immune globulin (ivig)	1
outcomes are the best with hla-matched, related donors	1
matched unrelated donor	1
umbilical cord blood donor	1
all individuals were alive at a median of 13	1
5 years of follow up	1
two individuals receiving myeloablative conditioning have developed premature ovarian failure	1
